Creatd has sold its remaining 80 per cent equity stake in its subsidiary Fly Flyte, a US technology-enabled regional air mobility company, to Catheter Precision. Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in convertible preferred stock of Catheter Precision. The NYSE-approved transaction considerably strengthens Creatd's balance sheet.

The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Creatd as a significant shareholder in Catheter.

Creatd acquired Flyte approximately one year ago, after initiating due diligence in Q4 2024, and implemented a disciplined turnaround strategy built around operational optimisation, technology integration and targeted revenue growth, while positioning the company for acquisition by a nationally-listed platform.

Creatd initially acquired its position in Flyte using a combination of financing and its then OTC Pink Sheet common stock, whereas the premium exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.

“Creatd will continue to pursue its own national exchange listing strategy this year. The plan is to do so without relying on the traditional financing structures that often accompany those transactions. Typically those structures consume companies that have not first generated their own balance sheet value,” says Jeremy Frommer, chairman and CEO of Creatd. “Our recent reverse split, completed without an accompanying financing, was an important step toward meeting those national exchange listing requirements. This asset sale now provides the capital needed to complete the next phase.”

“Our balance sheet value is created through acquisition and incubation strategies for exchange-listed entities, where operating businesses can develop and position themselves for long term success. At the same time, Creatd is building value from a portfolio of investments that leverage proprietary technology and process.”

“Creatd represents one of the few turnaround-focused publicly traded platforms in the small-cap and micro-cap M&A space. We intend to institutionalise this model as we expand and broaden our company's platform,” continues Frommer.

“We also see a significant opportunity to address the structural gap created by the contraction of the middle market over the past two decades. Too many public companies today lack the infrastructure and support needed to reach their full potential. We are building a platform that helps companies stabilise, scale and ultimately reach national exchange listings while creating lasting value.”